Hanmi Science Co Ltd (Hanmi Science) is a pharmaceutical company. It carries out research, development, and commercialization of various active pharmaceutical ingredients, key intermediates, Cephalosporin APIs, Cephalosporin finished dosage forms in both prescription and over-the counter markets. Hanmi Science’s prescription drugs include antidepressant, NSAIDs, neuropathic pain, oral care, hair growth, anti-inflammatory, osteoporos and diabetes, among others. The company’s OTC drugs consist of NSAIDs, oral care, calcium supplement, myalgia, vitamins nutritional supplements, and hypnotics, among others. It operates through two business units as Hanmi Science and Hanmi Pharmaceutical. The company supplies its products across the world. Hanmi Science is headquartered in Hwaseong, Gyeonggi-do, South Korea.
Headquarters
South Korea
Address
214, Muha-Ro, Paltan-Myeon, Hwaseong, 18536
Website
www.hanmiscience.co.kr
Telephone
82 2 4100447
No of Employees
98
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
008930 ()
Revenue (2021)
$830.5M
10.8%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
90%
(2021 vs 2020)
Market Cap*
$2.0B
Net Profit Margin (2021)
XXX
71.2%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products |
|---|
| Active Pharmaceutical Ingredients |
| Key Intermediates |
| Cephalosporin API's |
| XXX |
| XXX |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Contracts/Agreements | In October, the company and the University of Oxford entered into a partnership to prevent new and mutated infectious diseases. |
| 2021 | Contracts/Agreements | In January, the company entered into a strategic collaboration with Syntekabio to co-develop COVID-19 treatments by using drug repositioning technologies. |
| 2020 | Contracts/Agreements | In September, the company entered into an agreement with Merck to develop Efinopegdutide for the treatment of nonalcoholic steatohepatitis. |
Competitor Comparison
| Key Parameters | Hanmi Science Co Ltd | Easy Bio Inc | Chong Kun Dang Pharmaceutical Corp | Daewoong Pharmaceutical Co Ltd | JW Holdings Corp |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Hwaseong | Seoul | Seoul | Hwaseong | Seoul |
| No. of Employees | 98 | 182 | 1,904 | 1,256 | 161 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Song Young-sook | Chief Executive Officer; Director | Executive Board | 2020 | - |
| Taeseon Kwak | Director | Non Executive Board | 2022 | - |
| Woo Jong-soo | Director | Non Executive Board | 2020 | - |
| Shin Yoo-chul | Director | Non Executive Board | 2022 | - |
| Kim Yong-deok | Director | Non Executive Board | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer